HSBC Initiates Coverage On Pfizer with Buy Rating, Announces Price Target of $50
Portfolio Pulse from richadhand@benzinga.com
HSBC analyst Rajesh Kumar has initiated coverage on Pfizer (NYSE:PFE) with a Buy rating and a price target of $50.
July 14, 2023 | 9:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HSBC has initiated coverage on Pfizer with a Buy rating and a price target of $50, which could potentially boost investor confidence in the stock.
The Buy rating and price target of $50 announced by HSBC for Pfizer indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term as it may boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100